AbbVie 
Welcome,         Profile    Billing    Logout  
 283 Products   1083 Diseases   283 Products   2044 Trials   116790 News 


12345678910111213...10961097»
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Genetic diversity of KPC-2-producing Klebsiella pneumoniae complex from aquatic ecosystems. (Pubmed Central) -  Apr 24, 2024   
    In this context, some clones were reported for the first time in the environmental sector. Therefore, these findings evidence the occurrence of carbapenemase-producing K. pneumoniae complex strains in aquatic ecosystems and contribute to the monitoring of carbapenem resistance worldwide.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  National trends in prescription drug expenditures and projections for 2024. (Pubmed Central) -  Apr 24, 2024   
    For 2024, we expect overall prescription drug spending to rise by 10.0% to 12.0%, whereas in clinics and hospitals we anticipate an 11.0% to 13.0% increase and a 0% to 2.0% increase, respectively, compared to 2023. These national estimates of future pharmaceutical expenditure growth may not be representative of any health system because of the myriad of local factors that influence actual spending.
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / AbbVie, Avastin (bevacizumab) / Roche
    Review, Journal:  Intravitreal OZURDEX vs. Intravitreal Bevacizumab for Diabetic Macular Edema: A Comprehensive Review. (Pubmed Central) -  Apr 24, 2024   
    Collaboration among healthcare providers is essential for the comprehensive management of DME. Future research should focus on long-term comparative studies, predictors of treatment response, and exploration of novel therapeutic targets to optimize treatment outcomes for patients with DME.
  • ||||||||||  Venclexta (venetoclax) / Roche, AbbVie
    Journal:  Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens. (Pubmed Central) -  Apr 24, 2024   
    Similarly, severe infections, bleeding, and thromboembolic events were equally observed between early and later treatments, both in the overall patient groups and specific subgroups (age ?75 years or leukocytes ?20x109/L). This retrospective analysis indicates that delaying the start of venetoclax-based therapy in newly diagnosed acute myeloid leukemia might be a safe option for selected patients, provided that close clinical monitoring is performed.
  • ||||||||||  Darzalex (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
    PK/PD data, Journal, IO biomarker:  CD38-Specific Gallium-68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET. (Pubmed Central) -  Apr 24, 2024   
    In conclusion, [68 Ga]Ga-AJ206 exhibits the salient features required for clinical translation, providing CD38-specific high-contrast images in multiple models of MM. [68 Ga]Ga-AJ206-PET could be useful for quantifying total CD38 levels and pharmacodynamics during therapy to evaluate approved and new therapies in MM and other diseases with CD38 involvement.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Journal:  Hepatitis C Virus Antiviral Drug Resistance and Salvage Therapy Outcomes Across Australia. (Pubmed Central) -  Apr 23, 2024   
    In our cohort, the SVR rate for sofosbuvir/velpatasvir/voxilaprevir was higher than with other salvage regimens. The presence of NS5A, NS5B, or NS3 RASs did not appear to negatively influence retreatment outcomes.
  • ||||||||||  Journal:  Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month (Pubmed Central) -  Apr 23, 2024   
    Clinical Trials registration NCT02236000. This real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail involvement had significantly faster and more substantial improvements in nail psoriasis up to month
  • ||||||||||  navitoclax (ABT 263) / AbbVie
    Journal:  Cadherin-11 targeted cell-specific liposomes enabled skin fibrosis treatment by inducing apoptosis. (Pubmed Central) -  Apr 23, 2024   
    The findings from in vitro and in vivo studies confirmed that selectivity of LPS was improved towards CDH11 expressing myofibroblasts, thereby improving therapeutic efficacy with no indication of adverse effects. Hence, this novel research work represents a versatile LPS strategy that exhibits promising potential for treating skin fibrosis.
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    Journal:  Computational Investigation of the Covalent Inhibition Mechanism of Bruton's Tyrosine Kinase by Ibrutinib. (Pubmed Central) -  Apr 23, 2024   
    of the acrylamide warhead from the cysteine involving one or a few water molecules and a more indirect pathway involving a long-lived enolate intermediate state following the escape of the proton to the bulk solution. The results are compared with experiments by simulating the long-time kinetics of the reaction using kinetic modeling.
  • ||||||||||  Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma, navitoclax (ABT 263) / AbbVie
    Journal, Synthetic lethality:  OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma. (Pubmed Central) -  Apr 23, 2024   
    In patient-derived xenograft models of GBM in mice, the combination treatment of ABT263 and CPI-613 suppressed tumor growth and extended animal survival more potently than each compound on its own. Therefore, combined inhibition of Bcl-xL along with interference of the TCA-cycle might be a treatment strategy for GBM.
  • ||||||||||  Rinvoq (upadacitinib) / AbbVie, Sotyktu (deucravacitinib) / BMS, Jyseleca (filgotinib) / Galapagos, Gilead, SOBI
    Journal:  Janus kinase inhibitors differentially inhibit specific cytokine signals in the mesenteric lymph node cells of IBD patients. (Pubmed Central) -  Apr 23, 2024   
    Any consideration for de-escalation of biologic therapy in IBD must be tailored, taking into account the risks and consequences of a flare and patients' preferences. Despite their similarities, differences exist in the relative potencies of different JAKinibs against distinct cytokine families, to explain their clinical efficacy.
  • ||||||||||  Priligy (dapoxetine) / AbbVie
    Journal, Combination therapy:  Research progress of combination therapy in the treatment of erectile dysfunction and premature ejaculation comorbidity (Pubmed Central) -  Apr 23, 2024   
    In recent years, multi-country clinical guidelines have provided suggestions and guidance for the combination of these two drugs, with the safety and effectiveness being further explored and verified. This review summarized the status of ED and PE comorbidity, treatment principles, and research progress on the safety and effectiveness of Dapoxetine combined with PDE5i, in order to provide reference for the combination therapy of ED and PE comorbidity.
  • ||||||||||  Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
    Journal:  Risankizumab as a Therapeutic Approach for Recalcitrant Pyoderma Gangrenosum. (Pubmed Central) -  Apr 22, 2024   
    Systemic therapy was combined with local management of ulcers, based on the principles of TIME (tissue, infection, moisture balance, and epithelialization) applied to the inflammatory and noninflammatory phases of PG.?Clinical resolution was obtained at week 24 for patient 1 and week 16 for patient 2 and was maintained until week 40, without adverse effects or disease recurrence. These clinical cases demonstrate that risankizumab is a valid tool in terms of efficacy and safety for complicated cases of multirefractory PG when provided in parallel with local personalized wound management.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Cochlear implantation in patients with autoimmune hearing loss (Pubmed Central) -  Apr 22, 2024   
    These clinical cases demonstrate that risankizumab is a valid tool in terms of efficacy and safety for complicated cases of multirefractory PG when provided in parallel with local personalized wound management. Cochlear implantation can be necessary in some AIED patients and poses a
  • ||||||||||  Imbruvica (ibrutinib) / AbbVie, J&J
    Journal:  Ibrutinib in CLL: benefit for all? (Pubmed Central) -  Apr 22, 2024   
    However, information on the relative effectiveness and complication rates across the different therapies is limited. No abstract available
  • ||||||||||  Fetroja (cefiderocol) / Shionogi, Xerava (eravacycline) / SOM Biotech, Ewha Womans University, PAION, Innoviva, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Preclinical, Journal:  Evaluation of the in vitro susceptibility of clinical isolates of NDM-producing Klebsiella pneumoniae to new antibiotics included in a treatment regimen for infections. (Pubmed Central) -  Apr 22, 2024   
    Using the "strip stacking" method, determining cumulative sensitivity to ceftazidime/avibactam and aztreonam demonstrated 100% in vitro sensitivity to this combination among the tested strains...Due to the safety of using both drugs, cost effectiveness, and the broadest indications for use among the tested antibiotics, this therapy should be the first-line treatment for carbapenemase-producing Enterobacterales infections. Nevertheless, a comprehensive evaluation of the efficacy of treating infections caused by NDM-producing K. pneumoniae strains should include not only in vitro susceptibility assessment but also an analysis of clinical cases.
  • ||||||||||  Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab-vfrm) / Teva, Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
    Review, Journal, Adverse events, Serious adverse event:  Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. (Pubmed Central) -  Apr 22, 2024   
    All drugs showed a certain incidence of infections and infestations, with Onabotulinumtoxin A (BTA) having the lowest rate...Calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) such as fremanezumab and galcanezumab were linked to more general disorders and administration site conditions than other drugs...We suggest conducting head-to-head RCTs to evaluate the safety profile of oral medications, BTA, and CGRP MAbs in episodic and/or chronic migraine populations. CRD42021265993.
  • ||||||||||  Humira (adalimumab) / AbbVie
    Journal:  Vitiligo in a Patient Receiving Adalimumab for Idiopathic Uveitis. (Pubmed Central) -  Apr 22, 2024   
    As the inflammation did not resolve with local treatment, systemic cyclosporine was administered, after which the patient exhibited vomiting and weakness...Due to the persistence of intraocular inflammation and on the recommendation of the dermatology clinic, adalimumab treatment was continued and topical tacrolimus was started for the lesion...Taken together with the previous literature findings, no pathology was found in the patient's systemic examination, suggesting that this lesion was a side effect of the treatment. Ophthalmologists should be alert for this side effect in patients receiving adalimumab.